WHO recommends dolutegravir as preferred HIV treatment

Извор: Светска здравствена организација – 22.07.2019

Based on new evidence assessing benefits and risks, WHO recommends the use of the HIV drug dolutegravir (DTG) as the preferred first-line and second-line treatment for all populations, including pregnant women and those of childbearing potential. 

DTG is a drug that is more effective, easier to take and has fewer side effects than alternative drugs that are currently used. DTG also has a high genetic barrier to developing drug resistance.

Read the press release

More about HIV

 

© 2011 healthrights.mk. All Rights Reserved. ESE
Copyright 2011. Joomla 1.7 templates. © 2011 healthrights.mk. All Rights Reserved. ESE